INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 15 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $13,769,000 | -8.3% | 21,000,000 | -16.0% | 0.02% | -10.5% |
| Q4 2020 | $15,009,000 | -9.6% | 25,000,000 | +5.0% | 0.02% | -17.4% |
| Q3 2020 | $16,598,000 | +192.6% | 23,800,000 | +205.1% | 0.02% | +155.6% |
| Q2 2020 | $5,673,000 | -36.4% | 7,800,000 | -24.3% | 0.01% | -43.8% |
| Q1 2020 | $8,917,000 | -35.1% | 10,300,000 | 0.0% | 0.02% | -20.0% |
| Q4 2019 | $13,731,000 | -5.0% | 10,300,000 | -35.6% | 0.02% | -16.7% |
| Q3 2019 | $14,460,000 | +41.8% | 16,000,000 | +56.0% | 0.02% | +41.2% |
| Q2 2019 | $10,198,000 | – | 10,255,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
| PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
| Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
| Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
| Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
| Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
| Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
| CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |